Integrated sales up 7% excluding glyphosate
● ELATUS™ sales in Brazil exceed $300m
● Double digit growth in emerging markets for
fifth consecutive year
● Adverse currency and mix effects: profitability
below expectations
● Accelerating Operational Leverage program on
track to deliver savings